Nanodelivery of cerebrolysin reduces pathophysiology of Parkinson's disease

Asya Ozkizilcik; Aruna Sharma; José Vicente Lafuente; Dafin F. Muresanu; Rudy J. Castellani; Ala Nozari; Z. Ryan Tian; Herbert Mössler; Hari Shanker Sharma

doi:10.1016/bs.pbr.2019.03.014

Nanodelivery of cerebrolysin reduces pathophysiology of Parkinson's disease

Asya Ozkizilcik, Aruna Sharma, José Vicente Lafuente, Dafin F. Muresanu, Rudy J. Castellani, Ala Nozari, Z. Ryan Tian, Herbert Mössler, Hari Shanker Sharma^*

^*Corresponding author for this work

Pathology

Research output: Chapter in Book/Report/Conference proceeding › Chapter

24 Scopus citations

Abstract

Parkinson's disease (PD) is affecting > 10 million people worldwide for which no suitable cure has been developed so far. Roughly, about two people per thousand populations are affected with PD like symptoms especially over the age of 50. About 1% of the populations above 60 years suffer from PD-like disease. The prevalence of the disease is increasing over the years, and future projections by 2020 could be 12–14 millions people affected by the disease. Thus, exploration of suitable therapeutic measures is the need of the hour to enhance quality of the life of PD patients. PD induced brain pathology includes loss of dopaminergic neurons in the substantia niagra that could later extends to other cortical regions causing loss of voluntary motor control. Deposition of α-synuclein in the brain further leads to neurodegeneration. However, the exact cause of PD is still unknown. It appears that breakdown of the blood-brain barrier (BBB) and leakage of serum component into the brain could lead to neurodegeneration in PD. Thus, novel treatment strategies that are able to restore BBB breakdown and enhance neuronal plasticity and neuroregeneration in PD could be effective in future therapy. With the advancement of nanotechnology, it is worthwhile to understand the role of nanodelivery of selected agents in PD to enhance neuroprotection. In this review new role of BBB, brain edema, and neuropathology in PD is discussed. In addition, superior neuroprotection induced by nanowired delivery of a multimodal drug cerebrolysin in PD is summarized based on our own investigations.

Original language	English (US)
Title of host publication	Nanoneuroprotection and Nanoneurotoxicology
Editors	Aruna Sharma, Hari Shanker Sharma
Publisher	Elsevier B.V.
Pages	201-246
Number of pages	46
ISBN (Print)	9780444642080
DOIs	https://doi.org/10.1016/bs.pbr.2019.03.014
State	Published - Jan 1 2019

Publication series

Name	Progress in Brain Research
Volume	245
ISSN (Print)	0079-6123
ISSN (Electronic)	1875-7855

Funding

Supported by grants from the Air Force Office of Scientific Research (EOARD, London, United Kingdom), and Air Force Material Command, USAF, under Grant number FA8655-05-1-3065; supported by Grants from the Alzheimer's Association (IIRG-09-132087), the National Institutes of Health (R01 AG028679) and the Dr. Robert M. Kohrman Memorial Fund (M.A.S., R.J.C.); Swedish Medical Research Council (Nr 2710-HSS), Göran Gustafsson Foundation, Stockholm, Sweden (H.S.S.), Astra Zeneca, Mölndal, Sweden (H.S.S./A.S.), The University Grants Commission, New Delhi, India (HSS/AS), Ministry of Science & Technology, Govt. of India (H.S.S./A.S.), Indian Medical Research Council, New Delhi, India (H.S.S./A.S.) and India-EU Co-operation Program (RP/AS/HSS); Society for Neuroprotection and Neuroplasticity (SSNN), Romania; University of the Basque Country (PPG 17/51) and the Government of the Basque Country (IT-901/16) (J.V.L.). Technical and human support provided by Dr. Ricardo Andrade from SGIker (UPV/EHU) is gratefully acknowledged. We thank Suraj Sharma, Uppsala, Sweden for computer and graphic support. The U.S. Government is authorized to reproduce and distribute reprints for Government purpose notwithstanding any copyright notation thereon. The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of the Air Force Office of Scientific Research or the U.S. Government. Supported by grants from the Air Force Office of Scientific Research (EOARD, London, United Kingdom), and Air Force Material Command, USAF, under Grant number FA8655-05-1-3065; supported by Grants from the Alzheimer's Association (IIRG-09-132087), the National Institutes of Health (R01 AG028679) and the Dr. Robert M. Kohrman Memorial Fund (M.A.S. R.J.C.); Swedish Medical Research Council (Nr 2710-HSS), G?ran Gustafsson Foundation, Stockholm, Sweden (H.S.S.), Astra Zeneca, M?lndal, Sweden (H.S.S./A.S.), The University Grants Commission, New Delhi, India (HSS/AS), Ministry of Science & Technology, Govt. of India (H.S.S./A.S.), Indian Medical Research Council, New Delhi, India (H.S.S./A.S.) and India-EU Co-operation Program (RP/AS/HSS); Society for Neuroprotection and Neuroplasticity (SSNN), Romania; University of the Basque Country (PPG 17/51) and the Government of the Basque Country (IT-901/16) (J.V.L.). Technical and human support provided by Dr. Ricardo Andrade from SGIker (UPV/EHU) is gratefully acknowledged. We thank Suraj Sharma, Uppsala, Sweden for computer and graphic support. The U.S. Government is authorized to reproduce and distribute reprints for Government purpose notwithstanding any copyright notation thereon. The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of the Air Force Office of Scientific Research or the U.S. Government.

Keywords

Alpha-synuclein
Blood-brain barrier
Brain edema
Cerebrolysin
Nanowired delivery
Parkinson's disease

ASJC Scopus subject areas

General Neuroscience

Access to Document

10.1016/bs.pbr.2019.03.014

Cite this

Ozkizilcik, A., Sharma, A., Lafuente, J. V., Muresanu, D. F., Castellani, R. J., Nozari, A., Tian, Z. R., Mössler, H., & Sharma, H. S. (2019). Nanodelivery of cerebrolysin reduces pathophysiology of Parkinson's disease. In A. Sharma, & H. S. Sharma (Eds.), Nanoneuroprotection and Nanoneurotoxicology (pp. 201-246). (Progress in Brain Research; Vol. 245). Elsevier B.V.. https://doi.org/10.1016/bs.pbr.2019.03.014

@inbook{bde8418dc5ca4d9d9ba49dc8711f5d63,

title = "Nanodelivery of cerebrolysin reduces pathophysiology of Parkinson's disease",

abstract = "Parkinson's disease (PD) is affecting > 10 million people worldwide for which no suitable cure has been developed so far. Roughly, about two people per thousand populations are affected with PD like symptoms especially over the age of 50. About 1% of the populations above 60 years suffer from PD-like disease. The prevalence of the disease is increasing over the years, and future projections by 2020 could be 12–14 millions people affected by the disease. Thus, exploration of suitable therapeutic measures is the need of the hour to enhance quality of the life of PD patients. PD induced brain pathology includes loss of dopaminergic neurons in the substantia niagra that could later extends to other cortical regions causing loss of voluntary motor control. Deposition of α-synuclein in the brain further leads to neurodegeneration. However, the exact cause of PD is still unknown. It appears that breakdown of the blood-brain barrier (BBB) and leakage of serum component into the brain could lead to neurodegeneration in PD. Thus, novel treatment strategies that are able to restore BBB breakdown and enhance neuronal plasticity and neuroregeneration in PD could be effective in future therapy. With the advancement of nanotechnology, it is worthwhile to understand the role of nanodelivery of selected agents in PD to enhance neuroprotection. In this review new role of BBB, brain edema, and neuropathology in PD is discussed. In addition, superior neuroprotection induced by nanowired delivery of a multimodal drug cerebrolysin in PD is summarized based on our own investigations.",

keywords = "Alpha-synuclein, Blood-brain barrier, Brain edema, Cerebrolysin, Nanowired delivery, Parkinson's disease",

author = "Asya Ozkizilcik and Aruna Sharma and Lafuente, {Jos{\'e} Vicente} and Muresanu, {Dafin F.} and Castellani, {Rudy J.} and Ala Nozari and Tian, {Z. Ryan} and Herbert M{\"o}ssler and Sharma, {Hari Shanker}",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier B.V.",

year = "2019",

month = jan,

day = "1",

doi = "10.1016/bs.pbr.2019.03.014",

language = "English (US)",

isbn = "9780444642080",

series = "Progress in Brain Research",

publisher = "Elsevier B.V.",

pages = "201--246",

editor = "Aruna Sharma and Sharma, {Hari Shanker}",

booktitle = "Nanoneuroprotection and Nanoneurotoxicology",

}

Ozkizilcik, A, Sharma, A, Lafuente, JV, Muresanu, DF, Castellani, RJ, Nozari, A, Tian, ZR, Mössler, H & Sharma, HS 2019, Nanodelivery of cerebrolysin reduces pathophysiology of Parkinson's disease. in A Sharma & HS Sharma (eds), Nanoneuroprotection and Nanoneurotoxicology. Progress in Brain Research, vol. 245, Elsevier B.V., pp. 201-246. https://doi.org/10.1016/bs.pbr.2019.03.014

Nanodelivery of cerebrolysin reduces pathophysiology of Parkinson's disease. / Ozkizilcik, Asya; Sharma, Aruna; Lafuente, José Vicente et al.
Nanoneuroprotection and Nanoneurotoxicology. ed. / Aruna Sharma; Hari Shanker Sharma. Elsevier B.V., 2019. p. 201-246 (Progress in Brain Research; Vol. 245).

Research output: Chapter in Book/Report/Conference proceeding › Chapter

TY - CHAP

T1 - Nanodelivery of cerebrolysin reduces pathophysiology of Parkinson's disease

AU - Ozkizilcik, Asya

AU - Sharma, Aruna

AU - Lafuente, José Vicente

AU - Muresanu, Dafin F.

AU - Castellani, Rudy J.

AU - Nozari, Ala

AU - Tian, Z. Ryan

AU - Mössler, Herbert

AU - Sharma, Hari Shanker

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Parkinson's disease (PD) is affecting > 10 million people worldwide for which no suitable cure has been developed so far. Roughly, about two people per thousand populations are affected with PD like symptoms especially over the age of 50. About 1% of the populations above 60 years suffer from PD-like disease. The prevalence of the disease is increasing over the years, and future projections by 2020 could be 12–14 millions people affected by the disease. Thus, exploration of suitable therapeutic measures is the need of the hour to enhance quality of the life of PD patients. PD induced brain pathology includes loss of dopaminergic neurons in the substantia niagra that could later extends to other cortical regions causing loss of voluntary motor control. Deposition of α-synuclein in the brain further leads to neurodegeneration. However, the exact cause of PD is still unknown. It appears that breakdown of the blood-brain barrier (BBB) and leakage of serum component into the brain could lead to neurodegeneration in PD. Thus, novel treatment strategies that are able to restore BBB breakdown and enhance neuronal plasticity and neuroregeneration in PD could be effective in future therapy. With the advancement of nanotechnology, it is worthwhile to understand the role of nanodelivery of selected agents in PD to enhance neuroprotection. In this review new role of BBB, brain edema, and neuropathology in PD is discussed. In addition, superior neuroprotection induced by nanowired delivery of a multimodal drug cerebrolysin in PD is summarized based on our own investigations.

AB - Parkinson's disease (PD) is affecting > 10 million people worldwide for which no suitable cure has been developed so far. Roughly, about two people per thousand populations are affected with PD like symptoms especially over the age of 50. About 1% of the populations above 60 years suffer from PD-like disease. The prevalence of the disease is increasing over the years, and future projections by 2020 could be 12–14 millions people affected by the disease. Thus, exploration of suitable therapeutic measures is the need of the hour to enhance quality of the life of PD patients. PD induced brain pathology includes loss of dopaminergic neurons in the substantia niagra that could later extends to other cortical regions causing loss of voluntary motor control. Deposition of α-synuclein in the brain further leads to neurodegeneration. However, the exact cause of PD is still unknown. It appears that breakdown of the blood-brain barrier (BBB) and leakage of serum component into the brain could lead to neurodegeneration in PD. Thus, novel treatment strategies that are able to restore BBB breakdown and enhance neuronal plasticity and neuroregeneration in PD could be effective in future therapy. With the advancement of nanotechnology, it is worthwhile to understand the role of nanodelivery of selected agents in PD to enhance neuroprotection. In this review new role of BBB, brain edema, and neuropathology in PD is discussed. In addition, superior neuroprotection induced by nanowired delivery of a multimodal drug cerebrolysin in PD is summarized based on our own investigations.

KW - Alpha-synuclein

KW - Blood-brain barrier

KW - Brain edema

KW - Cerebrolysin

KW - Nanowired delivery

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=85063674695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063674695&partnerID=8YFLogxK

U2 - 10.1016/bs.pbr.2019.03.014

DO - 10.1016/bs.pbr.2019.03.014

M3 - Chapter

C2 - 30961868

AN - SCOPUS:85063674695

SN - 9780444642080

T3 - Progress in Brain Research

SP - 201

EP - 246

BT - Nanoneuroprotection and Nanoneurotoxicology

A2 - Sharma, Aruna

A2 - Sharma, Hari Shanker

PB - Elsevier B.V.

ER -

Nanodelivery of cerebrolysin reduces pathophysiology of Parkinson's disease

Abstract

Publication series

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this